← All Signals

🏥 FDA: Fresenius Kabi USA, LLC — Class II

healthcarebearishSource: FDA
90%Confidence
0Views
FDASource
2026-04-20Date

Summary

Another 500 mL saline product recall underscores the severity and scale of Fresenius Kabi's manufacturing deficiencies. The company may face increased regulatory inspections and potential production halts.

Actionable: Await Fresenius Kabi's official response and remediation plan before making any investment decisions.

AI Confidence: 90%

Data Points

firmFresenius Kabi USA, LLC
classificationClass II
statusOngoing
distributionUS Nationwide , Alaska, and Puerto Rico.
product0.9% Sodium Chloride Injection, USP, (4,500 mg per 500 mL) (9 mg per mL) 500 mL in a 500 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fresenius

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now